# To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets Under Non-Fasting Conditions

> **NCT00914160** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 18 (actual)

## Conditions studied

- Inflammation

## Interventions

- **DRUG:** Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)
- **DRUG:** Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)
- **DRUG:** Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)

## Key facts

- **NCT ID:** NCT00914160
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1993-08
- **Primary completion:** 1993-09
- **Final completion:** 1993-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00914160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00914160, "To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets Under Non-Fasting Conditions". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00914160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*